---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-079454"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-08-18T23:59:59+00:00"
generated_at: "2026-05-17T11:48:17.859468+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma gets HREC approval for Phase 2 COVID trials of ratutrelvir; top-line data expected year-end 2025

## Summary
- First Phase 2 non-inferiority trial compares ratutrelvir 600 mg QD for 10 days vs PAXLOVID 5-day regimen in newly diagnosed COVID subjects.
- Second single-arm trial tests ratutrelvir in PAXLOVID-ineligible patients; both trials expect top-line results by year-end 2025.
- Ratutrelvir is ritonavir-free, once-daily for 10 days, aiming to reduce clinical rebound and Long COVID risk.
- Pfizer reported $427M PAXLOVID sales in Q2 2025 (+70% YoY), highlighting continued market need for COVID treatments.

## SEC filing metadata
- accession: 0001104659-25-079454
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-08-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925079454/0001104659-25-079454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925079454/tm2523715d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-079454
- JSON: https://secwatch.observer/filing/0001104659-25-079454.json
- Plain text: https://secwatch.observer/filing/0001104659-25-079454.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.